696
Y. Ito et al. / Journal of Organometallic Chemistry 692 (2007) 691–697
3.87 (3H, s, OCH3), 4.93–5.02 (1H, m, CH), 6.72–6.81 (3H,
m, Ar). GC–MS (m/z) 164.
(1H, m, OCHHCH2), 4.20–4.31 (1H, m, CH), 4.40–4.48
(1H, m, OCHHCH2), 6.81–6.91 (3H, m, Ar). GC–MS
(m/z) 178.
3.6. 2,3-Dihydro-5-methoxy-2-methylbenzofuran (2d)
Acknowledgements
1H NMR(CDCl3) d 1.43 (3H, d, J = 6.79, CH3), 2.77
(1H, dd, J = 15.2, 7.6, CH2), 3.25 (1H, dd, J = 15.2, 7.6,
CH2), 3.73 (3H, s, OCH3), 4.83–4.91 (1H, m, CH),
6.61–6.67 (2H, m, Ar), 6.73 (1H, d, J = 2.4, Ar). GC–MS
(m/z) 164.
This work was partially supported by Doshisha Univer-
sity’s Research Promotion Fund, and a Grant to RCAST
at Doshisha University from the Ministry of Education,
Culture, Sports, Science and Technology, Japan. This work
was supported by Grant-in-Aid for Scientific Research on
Priority Areas (No. 16033259, ‘‘Reaction Control of Dy-
namic Complexes’’) from Ministry of Education, Japan.
3.7. 7-Chloro-2,3-dihydro-2-methylbenzofuran (2e)
1H NMR(CDCl3) d 1.51 (3H, d, J = 6.4, CH3), 2.89
(1H, dd, J = 16.0, 7.6, CH2), 3.41 (1H, dd, J = 16.0, 8.8,
CH2), 5.07–5.16 (1H, m, CH), 6.77 (1H, d, J = 8.8, Ar),
8.06–8.16 (2H, m, Ar). GC–MS (m/z) 179.
References
[1] (a) A.P. Monte, D. Marona-Lewicka, M.A. Parker, D.B. Wainscott,
D.L. Nelson, D.E. Nichols, J. Med. Chem. 39 (1996) 2953;
(b) G. Turan-Zitouni, S. Demirayak, K. Erol, M. Ozdemir, Ann.
Pharma. Franc. 54 (1996) 109, Chem. Abstr. 125 (1996) 75341;
(c) D. Fancelli, C. Caccia, M.G. Fornaretto, R. McArthur, D.
Severino, F. Vaghi, M. Varasi, Bioorg. Med. Chem. Lett. 6 (1996) 263;
(d) L. Pieters, T. De Bruyne, M. Claeys, A. Vlietinck, M. Calomme, D.
Vanden Berghe, J. Natur. Prod. 56 (1993) 899;
3.8. 3,4-Dihydro-2-methyl-2H-1-benzopyran (4)
1H NMR (CDCl3) d 1.39 (3H, d, J = 6.0, CH3), 1.65–
1.48 (1H, m, CH2CH2CH), 1.94–2.00 (1H, m,
CH2CH2CH), 2.70–2.76 (1H, ddd, J = 16.4, 3.2,
CH2CH2CH), 2.81–2.90 (1H, ddd, J = 16.4, 6.4, 3.2,
CH2CH2CH), 4.08–4.18 (1H, m, CH), 6.78–6.83 (2H, m,
Ar), 7.02–7.09 (2H, m, Ar). GC–MS (m/z) 148.
(e) N. Hirose, S. Kuriyama, S. Ozaki, S. Toyoshima, Chem. Pharma.
Bull. 24 (1976) 2912;
(f) T. Ohgoh, N. Hirose, N. Hashimoto, A. Kitahara, K. Miyao, Jpn.
J. Pharma. 21 (1971) 119.
[2] (a) A. Shah, Y. Naliapara, D. Sureja, N. Motohashi, T. Kurihara,
M. Kawase, K. Satoh, H. Sakagami, J. Molnar, Anticancer Res. 18
(1998) 61;
(b) A.E. Fenwick, Tetrahedron Lett. 34 (1993) 1815;
(c) D.A. Clark, S.W. Goldstein, R.A. Volkmann, J.F. Eggler, G.F.
Holland, B. Hulin, R.W. Stevenson, D.K. Kreutter, E.M. Gibbs, J.
Med. Chem. 34 (1991) 319;
(d) R. Mechoulam, N. Lander, M. Srebnik, A. Breuer, M. Segal, J.J.
Feigenbaum, T.U.C. Jarbe, P. Consroe, NIDA Res. Monogr. 79
(1987) 15, Chem. Abstr. 108 (1988) 124050;
3.9. 2-Methyl-N-tosylindoline (6)
1H NMR (CDCl3) d 1.46 (3H, d, J = 6.4, CHCH3), 2.38
(3H, s, ArCH3), 2.46 (1H, dd, J = 6.4, 3.2, CH2), 4.34–4.42
(1H, m, CH), 7.03–7.09 (2H, m, Ar), 7.187.26 (3H, m, Ar),
7.58 (2H, d, J = 8.4, Ar),7.69 (1H,d, J = 8.0, Ar). GC–MS
(m/z) 287.
(e) M. Shiratsuchi, K. Kawamura, T. Akashi, M. Fujii, H. Ishihama,
Y. Uchida, Chem. Pharm. Bull. 35 (1987) 632;
(f) A.K.M.N. Gohar, F.F. Abdel-Latif, M.S. El-Ktatny, Ind. J.
Chem., Sect. B: Org. Chem. Med. Chem. 25B (1986) 404;
(g) R.C. Schnur, R. Sarges, M.J. Peterson, J. Med. Chem. 25 (1982)
1451.
3.10. 3,4-Dihydro-2-methyl-2H-1,5-benzodioxepin (8)
1H NMR (CDCl3) d 1.40 (3H, d, J = 6.3, CH3), 1.95–
2.07 (1H, m, CH2CHHCH), 2.10–2.20 (1H, m,
CH2CHHCH), 4.00–4.07 (1H, m, OCHHCH2), 4.20–4.27
(1H, m, CH), 4.33–4.41 (1H, m, OCHHCH2), 6.87–6.97
(4H, m, Ar). GC–MS (m/z) 164.
[3] (a) A. Wissner, D.M. Berger, D.H. Boschelli, M.B. Floyd Jr., L.M.
Greenberger, B.C. Gruber, B.D. Johnson, N. Mamuya, R. Nilakan-
tan, M.F. Reich, R. Shen, H.-R. Tsou, E. Upeslacis, Y.F. Wang, B.
Wu, F. Ye, N. Zhang, J. Med. Chem. 43 (2000) 3244;
(b) V. Dauksas, P. Gaidelis, E. Udrenaite, L. Labanauskas, G.
Gasperaviciene, Chemija (1991) 116, Chem. Abstr. 118 (1993) 234026;
(c) M.R. Stillings, C.B. Chapleo, R.C.M. Butler, J.A. Davis, C.D.
England, M. Myers, P.L. Myers, N. Tweddle, A.P. Welbourn, J.
Med. Chem. 28 (1985) 1054;
3.11. 3,4-Dihydro-4-methyl-2H-1-benzopyran-8-ol (9)
(d) C.S. Rooney, W.C. Randall, K.B. Streeter, C. Ziegler, E.J.
Cragoe Jr., H. Schwam, S.R. Michelson, H.W.R. Williams, E.
Eichler, J. Med. Chem. 26 (1983) 700.
1H NMR (CDCl3) d 1.30 (3H, d, J = 6.9, CH3), 1.67–
1.79 (1H, m, CH2CHHCH), 2.05–2.15 (1H, m,
CH2CHHCH), 4.17–4.31 (2H, m, OCH2CH2), 5.51 (1H,
s, OH), 6.67–6.78 (3H, m, Ar). GC–MS (m/z) 164.
[4] (a) Acidic conditions see: D. Barton, W.D. Ollis, J.F. Stoddart
(Eds.), Comprehensive Organic Chemistry, vol. I, Pergamon, Oxford,
1979;
(b) J. March, Advanced Organic Chemistry, Reactions, Mechanisms,
and Structure, fourth ed., Wiley, New York, 1992, Chapter 15;
(c) J. Meinwald, J. Am. Chem. Soc. 77 (1955) 1617;
(d) P.E. Peterson, E.V.P. Tao, J. Org. Chem. 29 (1964) 2322;
(e) A.O. Fitton, R.K. Smalley, Practical Heterocyclic Chemistry,
Academic Press, New York, 1968, p. 16;
3.12. 3,4-Dihydro-2,6-dimethyl-2H-1,5-benzodioxepin (11)
1H NMR (CDCl3) d 1.46 (3H, d, J = 6.3, CH3), 2.01–
2.23 (2H, m, CH2CH2CH), 2.30 (3H, s, CH3), 4.02–4.10